Proton therapy for locally advanced non small cell lung cancer.
Radiation therapy is an essential component of treatment for locally advanced non small cell lung cancer (NSCLC) but can be technically challenging because of the proximity of lung tumors to nearby critical organs or structures. The most effective strategy for reducing radiation induced toxicity is to reduce unnecessary exposure of normal tissues by using advanced technology; examples from photon (X ray) therapy have included three dimensional conformal radiation therapy versus its predecessor, two dimensional radiation therapy, and intensity modulated photon radiation therapy versus its predecessor, three dimensional conformal therapy. Using particle beam therapy rather than photons offers the potential for further advantages because of the unique depth dose characteristics of the particles, which can be exploited to allow still higher dose escalation to tumors with greater sparing of normal tissues, with the ultimate goal of improving local tumor control and survival while preserving quality of life by reducing treatment related toxicity. However, the costs associated with particle therapy with protons are considerably higher than the current state of the art in photon technology, and evidence of clinical benefit from protons is increasingly being demanded to justify the higher financial burden on the healthcare system. Some such evidence is available from preclinical studies, from retrospective, single institution clinical series, from analyses of national databases, and from single arm prospective studies in addition to several ongoing randomized comparative trials. This review summarizes the rationale for and challenges of using proton therapy to treat thoracic cancers, reviews the current clinical experience, and suggests topics for future research.
The British journal of radiology